Iseganan HCl: A novel antimicrobial agent

Expert Opinion on Investigational Drugs

Volumn 11, Issue 8, 2002, Pages 1161-1170

  Giles, Francis J ^a   Redman, Rebecca ^a   Yazji, Salim ^a   Bellm, Lisa ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Antimicrobial peptides; Cystic fibrosis; Iseganan HCl; Oral mucositis; Protegrins; Stomatitis; Ventilator associated pneumonia

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DEFENSIN; DOXORUBICIN; FLUOROURACIL; IN 367; ISEGANAN; METHOTREXATE; MITOMYCIN C; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEGRIN; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL VENTILATION; BACTERICIDAL ACTIVITY; BODY FLUID; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPHAGIA; EPISTAXIS; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOST RESISTANCE; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; LUNG INFECTION; MOUTH MUCOSA; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; PAIN; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRURITUS; SEXUALLY TRANSMITTED DISEASE; STOMATITIS; THROAT; VOMITING;

EID: 0036053813     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.8.1161     Document Type: Article

References (60)

1. Mucositis as a biological process: A new hypothesis for the development of chemotherapy-induced stomatotoxicity
2. Mucositis associated with stem cell transplantation: Current status and innovative approaches to management
3. Patient reports of complications of bone marrow transplantation
4. Oral mucositis in myelosuppressive cancer therapy
5. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation
6. Toxicity in head and neck cancer: A review of trends and issues
7. The symptom experience of mucositis, stomatitis, and xerostomia
8. Quality of life and oral function in patients treated with radiation therapy for head and neck cancer
9. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis
10. Oral health and quality of life among patients with head and neck cancer or haematological malignancies
11. Mucositis in head and neck cancer: Economic and quality-of-life outcomes
12. Prevention and treatment of oral mucositis following cancer chemotherapy
13. Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: A review
14. Oral mucositis complicating chemotherapy and/or radiotherapy: Options for prevention and treatment
15. Epithelial antimicrobial peptides: Review and significance for oral applications
16. Protegrins: New antibiotics of mammalian origin
17. Sensitivity of periodontal pathogens to the bactericidal activity of synthetic protegrins, antibiotic peptides derived from porcine leukocytes
18. Antimicrobial peptides initiate il-1 beta posttranslational processing: A novel role beyond innate immunity
19. Development of protegrins for the treatment and prevention of oral mucositis: Structure-activity relationships of synthetic protegrin analogues
20. Ib-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis
21. Changing pharyngeal bacterial flora of hospitalized patients. Emergence of Gram-negative bacilli
22. Oral sources of septicaemia in patients with malignancies
23. Modifications of the microflora of the oral cavity arising during immunosuppressive chemotherapy
24. Do microorganisms play a role in irradiation mucositis?
25. The relationships among fluoride, cariogenic oral flora, and salivary flow rate during radiation therapy
26. IB-367 reduces the number of days of severe oral mucositis complicating myeloablative chemotherapy
27. Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters
28. A Phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomtatotoxic chemotherapy (PROMPT-CT trial)
29. Stomatotoxic manifestations of cancer chemotherapy
30. Guidelines for prevention of nosocomial pneumonia
31. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients
32. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, american thoracic society, november 1995
33. Nosocomial pneumonia. Diagnosis and prevention
34. The effect of selective decontamination of the digestive tract on colonisation and infection rate in multiple trauma patients
35. Prevention of colonization and respiratory infections in long-term ventilated patients by local antimicrobial prophylaxis
36. Prevention of colonization and infection in critically ill patients: A prospective randomized study
37. Triple regimen of selective decontamination of the digestive tract, systemic cefotaxime, and microbiological surveillance for prevention of acquired infection in intensive care
38. Selective decontamination of the digestive tract with norfloxacin in the prevention of icu-acquired infections: A prospective randomized study
39. Intestinal decontamination in a polyvalent icu. A double-blind study
40. Pilot trial of selective decontamination for prevention of bacterial infection in an intensive care unit
41. Prevention of nosocomial lung infection in ventilated patients: Use of an antimicrobial pharyngeal nonabsorbable paste
42. Oropharyngeal decontamination decreases incidence of ventilator-associated pneumonia. A randomized, placebo-controlled, double-blind clinical trial
43. A controlled trial in intensive care units of selective decontamination of the digestive tract with nonabsorbable antibiotics. The french study group on selective decontamination of the digestive tract
44. Prophylactic use of the new quinolones for prevention of nosocomial infection in the intensive care unit
45. Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery
46. Decrease in nosocomial pneumonia in ventilated patients by selective oropharyngeal decontamination (sod)
47. The prevention of ventilator-associated pneumonia
48. The damaging role of bacteria in chronic lung infection
49. Management of pulmonary disease in patients with cystic fibrosis
50. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
51. Aerosol carbenicillin and gentamicin treatment of pseudomonas aeruginosa infection in patients with cystic fibrosis
52. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis
53. Prevention of chronic pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
54. Susceptibility of neisseria gonorrhoeae to protegrins
55. Protegrins: Structural requirements for inactivating elementary bodies of chlamydia trachomatis
56. Haemophilus ducreyi is susceptible to protegrin
57. Evaluation of the inactivation of infectious herpes simplex virus by host-defense peptides
58. Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity
59. Protegrin structure and activity against neisseria gonorrhoeae
60. Susceptibility of chlamydia trachomatis to protegrins and defensins